22 citations,
November 2018 in “Breast Cancer Research and Treatment” The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
21 citations,
February 2021 in “BMJ case reports” Anabolic steroid users may face higher risk of severe COVID-19.
15 citations,
March 1997 in “International Journal of Dermatology” Finasteride shows promise for treating hair loss and excessive hair growth, but more research is needed to confirm its effectiveness and safety.
13 citations,
November 2012 in “PubMed” 5α-reductase inhibitors may worsen sexual drive and spontaneous erections but don't worsen existing erectile or ejaculatory problems.
10 citations,
December 2019 in “in Vivo” Testosterone makes the connections in the uterus lining simpler and lowers certain protein levels, which might lead to infertility.
10 citations,
November 2012 in “The journal of investigative dermatology/Journal of investigative dermatology” Korean and Caucasian men with male pattern baldness have different hair steroid levels.
9 citations,
February 2011 in “Biologics: Targets & Therapy” Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.
8 citations,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
6 citations,
March 2015 in “Journal of Endocrinological Investigation” Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.
1 citations,
June 2021 in “Journal of dermatology and dermatitis” Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.